奧地利Intercell AG www.intercell.com
Intercell AG系奧地利著名的生化科技公司，成立于1998年，2005年在維也納證券交易所上市，總公司及主要研究室位于維也納。 該公司目前進(jìn)行較大的幾項疫苗研發(fā)計畫包括：日本腦炎、B及C型肝炎、肺結(jié)核、肺炎、咽峽炎等疫苗等，就進(jìn)度而言，日本腦炎疫苗的研發(fā)目前處於臨床第三階段，C型肝炎疫苗為臨床第二階段。該公司目前進(jìn)行較大的幾項疫苗研發(fā)計畫包括：日本腦炎、B及C型肝炎、肺結(jié)核、肺炎、咽峽炎等疫苗等，就進(jìn)度而言，日本腦炎疫苗的研發(fā)目前處于臨床第三階段，C型肝炎疫苗為臨床第二階段。

Founded in 1998 as a spin-off from Vienna University, Intercell is an international and multicultural enterprise, with about 400 employees representing more than 30 different countries. 
Our corporate team: People with courage for innovation
Intercell is a knowledge-based company and the achievement of our ambitious goals relies strongly on our employees. Their expertise, professional experience and dedication are among the most important factors for our future development, growth and success. 
Of the total number of employees, about 220 are employed at the headquarters in Vienna, about 80 are working at our manufacturing site in Livingston, Scotland and about 100 at Intercell USA in Gaithersburg, Maryland. 
As of Dec. 31, 2008: 
73.5 percent are working in research, development and manufacturing and 26.6 percent within selling, general and administrative activities
60 percent of our employees are women and 40 percent are men
65 percent of our staff are university graduates
Intercell is a young and dynamic company, which is also reflected in our workforce with an average age of 36.8 years. 
Foundations of Intercell - Three units make a strong team
Intercell has a two-tiered board system consisting of a Supervisory Board and a Management Board. These consist of members with internationally renowned experience within the biotech field. Members are appointed individually, and no individual is allowed to serve on both Boards simultaneously, in accordance with the Austrian Stock Corporation Act.